David Xu, MD
Hematology & Oncology · Irvine, CANPI 1568826519
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $575 of the $696 with a category attached, or 82.6%. It is spread thinly across 9 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $313 and has fallen 71.1% since, to $91 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 10 payments — averaging $69.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Globus Medical$152
- Genentech USA, Inc.$140
- Bayer$120
- Seagen Inc.$100
- Bristol Myers Squibb$72
- Astellas Pharma Global Development$33
- plus $78 from 3 others
What the payments were for
- Food & beverage$57583%
- Education$12117%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Globus Medical | 1 | $152 |
| Genentech USA, Inc. | 1 | $140 |
| Bayer | 1 | $120 |
| Seagen Inc. | 1 | $100 |
| Bristol Myers Squibb | 2 | $72 |
| Astellas Pharma Global Development | 1 | $33 |
| Harrow Eye, LLC | 1 | $29 |
| Tempus AI, Inc | 1 | $29 |
| Mirati Therapeutics, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Direct Look$152
- VABYSMO$140
- Nubeqa$120
How this compares
$696 in reported general payments places this provider in the 25th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 20 | $45,614 |
| EliquisApixaban | 11 | $15,405 |
| Prednisone | 24 | $246 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $132 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Irvine
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.